TransMedics Group stock has more than doubled over the past five years, yet shares are currently well below recent highs. The broader valuation checks still suggest the stock is trading on the cheap side rather than at a clear premium.

• Over five years, TransMedics Group has delivered a 110.7% total return, which means long term holders are still ahead even after the recent pullback.
• Investor expectations around U.S. transplant procedure volumes, highlighted by recent commentary on growing heart, liver and lung activity, can support the business outlook. However, any slowdown in transplant growth or execution issues in its logistics operations may weigh on what investors are willing to pay.
• On Simply Wall St's broader checks, TransMedics Group screens as undervalued on most measures, with the stock passing 5 of 6 valuation tests, which you can see in more detail at 5/6.

The issue now is whether the recent share price reset already reflects the key risks around TransMedics Group, or if the current level still offers a margin of safety based on those valuation checks.

Is TransMedics Group Still Cheap on Earnings?

The P/E ratio is a useful way to think about what you are paying today for each dollar of TransMedics Group’s current earnings. On this measure, TransMedics Group trades at about 13.8x earnings, which is roughly half the Medical Equipment industry average of 25.6x and also well below the peer group average of 28.4x.

The fair P/E ratio implied by Simply Wall St’s model is 24.3x, which reflects what investors might typically pay given TransMedics Group’s sector, size and risk profile. The current 13.8x multiple sits meaningfully under that fair level, suggesting the recent pullback has left the stock pricing in more caution than the model indicates. Despite the positive sentiment following recent analyst commentary on transplant volumes, the market P/E still sits at a discount to both peers and this tailored fair ratio.

On the P/E multiple, TransMedics Group stock currently screens as undervalued compared with both its industry and the modelled fair ratio.

The TransMedics Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where those P/E checks leave off by spelling out which future paths for TransMedics Group's growth, margins and earnings would line up with a much higher or lower share price than today. They sit on the company’s Community page. Rather than relying on a single multiple or model output, each narrative lays out the assumptions behind its fair value so you can compare them with actual results as they are reported.

One of the top community narratives on TransMedics Group: 42% undervalued

"Development of a recurring, service-driven revenue model, including logistics, digital ecosystem, and service contracts, enables more predictable and stable cash flows..."

Do you think there's more to the story for TransMedics Group? Head over to our Community to see what others are saying!

The Bottom Line

TransMedics Group still screens as undervalued on market multiples, with the current P/E sitting well below both its industry and the tailored fair ratio discussed above. The key question is whether that discount compensates you for the execution risks around transplant volumes and logistics that could pressure earnings if they do not play out as expected. From here, the crux of the debate is whether TransMedics Group can deliver consistent growth and execution that eventually earns a higher multiple, or whether the current valuation reflects the market correctly pricing in those risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.